SEC Form 4 · accession 0001571049-17-005584
Cyclacel Pharmaceuticals, Inc. · CYCC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Sam L Barker
Director
Period of report
May 30, 2017
Accepted (ET)
Jun 1, 2017 · 5:04 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001130166
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $4.38 | May 30, 2017 | A | 2,000 | A | May 30, 2018 | May 30, 2027 | Common Stock | 2,000 | 2,000 | D |
Explanation of responses
- F1These options were granted to Dr. Barker for his services as a member of the board of directors of Cyclacel Pharmaceuticals, Inc.